Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
PLoS One ; 15(1): e0226895, 2020.
Article in English | MEDLINE | ID: mdl-31940319

ABSTRACT

OBJECTIVE: To estimate healthcare expenditures that could be impacted by advanced diagnostic testing for patients hospitalized with meningitis or encephalitis. METHODS: Patients hospitalized with meningitis (N = 23,933) or encephalitis (N = 7,858) in the U.S. were identified in the 2010-2014 Truven Health MarketScan Commercial Claims and Encounters Database using ICD-9-CM diagnostic codes. The database included an average of 40.8 million commercially insured enrollees under age 65 per year. Clinical, demographic and healthcare utilization criteria were used to identify patient subgroups early in their episode who were at risk to have high inpatient expenditures. Healthcare expenditures of patients within each subgroup were bifurcated: those expenditures that remained five days after the patient could be classified into the subgroup versus those that had occurred previously. RESULTS: The hospitalization episode rate per 100,000 enrollee-years for meningitis was 13.0 (95% CI: 12.9-13.2) and for encephalitis was 4.3 (95% CI: 4.2-4.4), with mean inpatient expenditures of $36,891 (SD = $92,636) and $60,181 (SD = $130,276), respectively. If advanced diagnostic testing had been administered on the day that a patient could be classified into a subgroup, then a test with a five-day turnaround time could impact the following mean inpatient expenditures that remained by subgroup for patients with meningitis or encephalitis, respectively: had a neurosurgical procedure ($83,337 and $56,020), had an ICU stay ($34,221 and $46,051), had HIV-1 infection or a previous organ transplant ($37,702 and $62,222), were age <1 year ($35,371 and $52,812), or had a hospital length of stay >2 days ($18,325 and $30,244). DISCUSSION: Inpatient expenditures for patients hospitalized with meningitis or encephalitis were substantial and varied widely. Patient subgroups who had high healthcare expenditures could be identified early in their stay, raising the potential for advanced diagnostic testing to lower these expenditures.


Subject(s)
Encephalitis/diagnosis , Encephalitis/economics , Health Expenditures/statistics & numerical data , Hospitalization , Meningitis/diagnosis , Meningitis/economics , Adult , Child , Child, Preschool , Encephalitis/therapy , Female , Humans , Infant , Infant, Newborn , Insurance, Health , Male , Meningitis/therapy , Middle Aged , Retrospective Studies , Young Adult
2.
Int J Pediatr Otorhinolaryngol ; 128: 109696, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31585355

ABSTRACT

BACKGROUND: Orbital and intracranial complications of pediatric acute rhinosinusitis (ARS) are uncommon. With a risk of significant morbidity, hospital utilization and the financial burden of these entities are often high. We sought to assess utilization trends for complicated ARS and elucidate which factors influence cost. METHODOLOGY: Analysis of Kids' Inpatient Database (2006, 2009 and 2012). Children were selected based on diagnosis codes for ARS and grouped as: uncomplicated ARS, orbital complications (OC), or intracranial complications (IC). Patients with IC were subdivided into abscess (ICa), meningitis, or sinus thrombosis. Length of stay (LOS), cost and management information were analysed. Data presented as median [IQR]. RESULTS: A weighted total of 20,775 children were included. OC and IC were observed in 10.9% and 2.7% of these patients. LOS was longer for IC compared to OC (9 [8] v 4 [3]days, p < 0.001). Daily cost for IC was greater than OC ($2861 [4044] v $1683 [1187], p < 0.001), likely due to differences in need for surgery (IC 66.3% v OC 37.1%, p < 0.001). Within the ICa group, patients who received both otolaryngologic (ENT) and neurosurgery, compared to neurosurgery alone, had higher total cost ($41,474 [41,976] v $32,299 [18,235], p < 0.001) but similar LOS (12 [10] v 11 [9] days, p = 0.783). CONCLUSIONS: Children with IC required more surgery than their OC counterparts, resulting in a longer LOS and increased cost. Within the ICa group, the addition of ENT surgery to neurosurgery resulted in higher costs, but with a similar LOS. Considering the increased costs, the additional benefit of ENT surgery to those with children with IC should be investigated further.


Subject(s)
Central Nervous System Diseases/economics , Health Care Costs/statistics & numerical data , Length of Stay/statistics & numerical data , Orbital Diseases/economics , Rhinitis/complications , Sinusitis/complications , Acute Disease , Adolescent , Brain Abscess/economics , Brain Abscess/etiology , Brain Abscess/surgery , Central Nervous System Diseases/etiology , Central Nervous System Diseases/surgery , Child , Databases, Factual , Female , Humans , Male , Meningitis/economics , Meningitis/etiology , Meningitis/surgery , Neurosurgical Procedures/economics , Orbital Diseases/etiology , Orbital Diseases/surgery , Otorhinolaryngologic Surgical Procedures/economics , Sinus Thrombosis, Intracranial/economics , Sinus Thrombosis, Intracranial/etiology , Sinus Thrombosis, Intracranial/surgery
3.
J Pharm Pract ; 32(1): 36-40, 2019 Feb.
Article in English | MEDLINE | ID: mdl-29092659

ABSTRACT

BACKGROUND:: Cerebrospinal fluid (CSF) Gram stain and culture along with CSF viral polymerase chain reaction (PCR) are the current standard of care (SOC) to diagnose meningitis. Unfortunately, these tests take up to 72 hours to provide results and are not always sensitive to detect a pathogen. BioFire FilmArray (FA) meningitis/encephalitis (ME) panel uses PCR to provide quick, accurate identification of the causative organism. For community hospitals, the cost of this technology may be prohibitive. OBJECTIVE:: To compare the institution cost of current SOC versus the anticipated cost of the FA ME panel to diagnose and treat suspected meningitis. METHODS:: A retrospective cohort study was conducted evaluating adult patients with a lumbar puncture performed and empiric antimicrobials administered for a diagnosis of meningitis. The time to receive CSF culture results and cost associated with empiric antimicrobials were assessed and compared to the theoretical time to results and cost of treatment using the FA ME panel. RESULTS:: Thirty-three patients were included in the analysis. The cost of antimicrobials using SOC was $63.43 versus $24.70 per treatment course if using the FA ME panel ( P < .001). When the cost of diagnostic testing supplies per patient was included, the median cost of SOC was $239.63 versus $239.14 per treatment course when using the FA ME panel ( P = .15). CONCLUSION:: There is potential for significant cost savings in direct antibiotic utilization if FA ME is used versus SOC to diagnose meningitis in a community hospital. Antimicrobial cost savings were able to offset the increased cost of testing.


Subject(s)
Anti-Infective Agents/administration & dosage , Encephalitis/diagnosis , Meningitis/diagnosis , Polymerase Chain Reaction/methods , Adult , Aged , Anti-Infective Agents/economics , Cohort Studies , Costs and Cost Analysis , Drug Costs , Encephalitis/economics , Female , Gentian Violet , Hospitals, Community , Humans , Male , Meningitis/economics , Middle Aged , Phenazines , Polymerase Chain Reaction/economics , Retrospective Studies , Spinal Puncture/methods , Standard of Care/economics , Time Factors
4.
Diagn Microbiol Infect Dis ; 93(4): 349-354, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30442508

ABSTRACT

A retrospective cohort study design was used to assess the use and costs of diagnostic tests, medication, and total hospitalization costs for pediatric patients with suspected meningitis/encephalitis who received a lumbar puncture (LP) procedure. Related costs were calculated by timing of LP performed and infectious etiology for infants (<1 year) and children (1-17 years). A total of 3030 infants and 3635 children with suspected ME diagnosed between 2011 and 2014 were included in the study. The mean hospitalization cost for infants and children was $12,759 and $11,119, respectively, with medication and laboratory test costs of $834 and $1771 for infants and $825 and $855 for children, respectively. Total visit cost increased with delayed LP procedure, ICU stay, and if the etiology was viral (other than enterovirus or arbovirus) or bacterial. Higher diagnostic and treatment costs were associated with delayed LP procedure, etiologic agent, and ICU stay.


Subject(s)
Encephalitis/economics , Health Care Costs , Hospitalization/economics , Meningitis/economics , Adolescent , Child , Child, Preschool , Encephalitis/diagnosis , Encephalitis/therapy , Female , Humans , Infant , Infant, Newborn , Male , Meningitis/diagnosis , Meningitis/therapy , Retrospective Studies , United States
5.
PLoS One ; 13(7): e0201245, 2018.
Article in English | MEDLINE | ID: mdl-30044865

ABSTRACT

BACKGROUND: The burden of pneumococcal disease in China is high, and a 13-valent pneumococcal conjugate vaccine (PCV13) recently received regulatory approval and is available to Chinese infants. PCV13 protects against the most prevalent serotypes causing invasive pneumococcal disease (IPD) in China, but will not provide full societal benefits until made broadly available through a national immunization program (NIP). OBJECTIVE: To estimate clinical and economic benefits of introducing PCV13 into a NIP in China using local cost estimates and accounting for variability in vaccine uptake and indirect (herd protection) effects. METHODS: We developed a population model to estimate the effect of PCV13 introduction in China. Modeled health states included meningitis, bacteremia, pneumonia (PNE), acute otitis media, death and sequelae, and no disease. Direct healthcare costs and disease incidence data for IPD and PNE were derived from the China Health Insurance and Research Association database; all other parameters were derived from published literature. We estimated total disease cases and associated costs, quality-adjusted life years (QALYs), and deaths for three scenarios from a Chinese Payer Perspective: (1) direct effects only, (2) direct+indirect effects for IPD only, and (3) direct+indirect effects for IPD and inpatient PNE. RESULTS: Scenario (1) resulted in 370.3 thousand QALYs gained and 12.8 thousand deaths avoided versus no vaccination. In scenarios (2) and (3), the PCV13 NIP gained 383.2 thousand and 3,580 thousand QALYs, and avoided 13.1 thousand and 147.5 thousand deaths versus no vaccination, respectively. In all three scenarios, the vaccination cost was offset by cost reductions from prevented disease yielding net costs of ¥29,362.32 million, ¥29,334.29 million, and ¥13,524.72 million, respectively. All resulting incremental cost-effectiveness ratios fell below a 2x China GDP cost-effectiveness threshold across a range of potential vaccine prices. DISCUSSION: Initiation of a PCV13 NIP in China incurs large upfront costs but is good value for money, and is likely to prevent substantial cases of disease among children and non-vaccinated individuals.


Subject(s)
Immunization Programs/economics , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/economics , Vaccines, Conjugate/economics , Bacteremia/economics , Bacteremia/epidemiology , Bacteremia/prevention & control , China/epidemiology , Cost of Illness , Cost-Benefit Analysis , Health Care Costs , Humans , Infant , Meningitis/economics , Meningitis/epidemiology , Meningitis/prevention & control , Models, Statistical , Otitis Media/economics , Otitis Media/epidemiology , Otitis Media/prevention & control , Pneumococcal Infections/economics , Pneumococcal Infections/epidemiology , Pneumonia/economics , Pneumonia/epidemiology , Pneumonia/prevention & control , Prevalence , Quality-Adjusted Life Years , Vaccination/economics
6.
Int J Infect Dis ; 71: 117-121, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29702265

ABSTRACT

OBJECTIVE: To determine the associated costs related to the diagnosis and treatment of meningitis and encephalitis (ME) in adult patients in the USA. METHODS: A retrospective observational study design was used to assess the use and costs of diagnostic tests and antimicrobial treatment and the total hospitalization costs for adult patients with suspected ME, who received a lumbar puncture procedure during an emergency department visit or during the first two service days of an inpatient stay. Related costs were calculated by timing of lumbar puncture performed and infectious etiology. RESULTS: A total 26429 adult patients with suspected ME diagnosed between 2011 and 2014 were included in the study. The mean hospitalization cost was $15 572±27168, with antimicrobial medication cost of $1144±4052 and laboratory test cost of $210±244. The total visit cost increased with delayed lumbar puncture procedure, intensive care unit stay, and if the etiology was fungi, arbovirus, or bacteria. CONCLUSIONS: Higher diagnostic and treatment costs are associated with a delayed lumbar puncture procedure, the etiological agent, and the requirement for an intensive care unit stay.


Subject(s)
Encephalitis/therapy , Health Care Costs , Meningitis/therapy , Adult , Encephalitis/economics , Female , Hospital Costs , Humans , Intensive Care Units/economics , Male , Meningitis/economics , Retrospective Studies , Spinal Puncture/economics , United States
7.
Pediatr Infect Dis J ; 36(9): 827-832, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28399052

ABSTRACT

BACKGROUND: Despite the benefits of home treatment with outpatient parenteral antimicrobial therapy (OPAT), children with pyelonephritis and meningitis are rarely included. We aimed to compare clinical characteristics and outcomes between hospital and home treatment for these conditions and to identify factors influencing home treatment. METHODS: Children admitted to the hospital with pyelonephritis or proven and presumed bacterial meningitis from January 1, 2012, to December 31, 2013 were identified retrospectively. Patients who received any OPAT (home group) received daily visits via our Hospital-in-the-Home (HITH) program; inpatients (hospital group) received standard care. Clinical and demographic features, length of stay, readmission rate and cost were compared between hospital and home groups. RESULTS: One hundred thirty-nine children with pyelonephritis and 70 with meningitis were identified, of which 127 and 44 were potentially suitable for OPAT, respectively. Of these, 12 (9%) with pyelonephritis received OPAT, contrasting with 29 (66%) with meningitis. Clinical features did not differ between hospital- and home-treated patients for either condition. Patients with meningitis in the hospital group were younger than those transferred to HITH (1 vs. 2 months; P = 0.01). All patients were afebrile before transfer to HITH. Admissions for pyelonephritis were brief with inpatients having a shorter length of stay than home patients (median: 3 vs. 4.5 days; P = 0.002). Unplanned readmission rates were comparable across all groups. Transfer to HITH resulted in a saving of AU$178,180. CONCLUSIONS: Children with pyelonephritis and meningitis can feasibly receive OPAT. Age, treatment duration and fever influence this decision. None of these should be barriers to OPAT, and the cost savings support change in practice.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Meningitis/drug therapy , Outpatients/statistics & numerical data , Pyelonephritis/drug therapy , Administration, Intravenous , Anti-Bacterial Agents/economics , Anti-Bacterial Agents/therapeutic use , Child , Child, Preschool , Cost Savings , Female , Home Care Services/economics , Hospitalization/economics , Humans , Infant , Male , Meningitis/economics , Meningitis/epidemiology , Pyelonephritis/economics , Pyelonephritis/epidemiology , Retrospective Studies , Victoria/epidemiology
8.
Eur J Health Econ ; 18(3): 273-292, 2017 Apr.
Article in English | MEDLINE | ID: mdl-26905404

ABSTRACT

BACKGROUND: In 2009, the European Medicines Agency granted approval for two higher-valent pneumococcal conjugate vaccines. This study aims to evaluate the cost-effectiveness of universal infant (<2 years old) vaccination with a 13-valent pneumococcal conjugate vaccine (PCV13) in comparison with a 10-valent pneumococcal conjugate vaccine (PCV10) for the prevention of pneumococcal disease in Germany. METHODS: A population-based Markov model was developed to estimate the impact of PCV13 and PCV10 on invasive pneumococcal disease (IPD), non-invasive pneumonia (PNE), and acute otitis media (AOM) over a time horizon of 50 years. The model included the effects of the historical vaccination scheme in infants as well as indirect herd effects and replacement disease. We used German epidemiological data to calculate episodes of IPD, PNE, and AOM, as well as direct and indirect effects of the vaccination. Parameter uncertainty was tested in univariate and probabilistic sensitivity analyses. RESULTS: In the base-case analysis, the ICER of PCV13 versus PCV10 infant vaccination was EUR 9826 per quality-adjusted life-year (QALY) gained or EUR 5490 per life-year (LY) gained from the societal perspective and EUR 3368 per QALY gained or EUR 1882 per LY gained from the perspective of the German statutory health insurance. The results were particularly sensitive to the magnitude of indirect effects of both vaccines. CONCLUSIONS: Universal infant vaccination with PCV13 is likely to be a cost-effective intervention compared with PCV10 within the German health care system, if additional net indirect effects of PCV13 vaccination are significant.


Subject(s)
Pneumococcal Infections/economics , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/administration & dosage , Pneumococcal Vaccines/economics , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Cost-Benefit Analysis , Germany , Humans , Immunity, Herd , Infant , Infant, Newborn , Markov Chains , Meningitis/economics , Meningitis/prevention & control , Middle Aged , Models, Statistical , Otitis Media/economics , Otitis Media/prevention & control , Pneumonia/economics , Pneumonia/prevention & control , Quality-Adjusted Life Years , Young Adult
9.
Vaccine ; 33 Suppl 1: A240-7, 2015 May 07.
Article in English | MEDLINE | ID: mdl-25919168

ABSTRACT

Meningitis infections are often associated with high mortality and risk of sequelae. The costs of treatment and care for meningitis are a great burden on health care systems, particularly in resource-limited settings. The objective of this study is to review data on the costs of care for meningitis in low- and middle-income countries, as well as to show how results could be extrapolated to countries without sound data. We conducted a systematic review of the literature from six databases to identify studies examining the cost of care in low- and middle-income countries for all age groups with suspected, probable, or confirmed meningitis. We extracted data on treatment costs and sequelae by infectious agent and/or pathogen, where possible. Using multiple regression analysis, a relationship between hospital costs and associated determinants was investigated in order to predict costs in countries with missing data. This relationship was used to predict treatment costs for all 144 low- and middle-income countries. The methodology of conducting a systematic review, extrapolating, and setting up a standard database can be used as a tool to inform cost-effectiveness analyses in situations where cost of care data are poor. Both acute and long-term costs of meningitis could be extrapolated to countries without reliable data. Although only bacterial causes of meningitis can be vaccine-preventable, a better understanding of the treatment costs for meningitis is crucial for low- and middle-income countries to assess the cost-effectiveness of proposed interventions in their country. This cost information will be important as inputs in future cost-effectiveness studies, particularly for vaccines.


Subject(s)
Health Care Costs , Meningitis/economics , Developing Countries , Humans , Models, Statistical
10.
Trop Med Int Health ; 19(11): 1321-7, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25130978

ABSTRACT

OBJECTIVE: To estimate the average treatment costs of pneumonia and meningitis among children under five years of age in a tertiary hospital in Hanoi, Vietnam from societal, health sector and household perspectives. METHODS: We used a cost-of-illness approach to identify cost categories to be included for different perspectives. A prospective survey was conducted among eligible patients to get detailed personal costing items. RESULTS: From the perspective of the health sector, the mean costs for treating a case of pneumonia and meningitis were USD 180 and USD 300, respectively. From the household's perspective, the average treatment costs were USD 272 for pneumonia and USD 534 for meningitis. When also including indirect costs, the average total treatment costs from the societal perspective were USD 318 for pneumonia and USD 727 for meningitis. CONCLUSION: The study contributed to limited evidence on the high treatment costs of pneumonia and meningitis to the Vietnamese society, which is useful for a cost-effectiveness analysis of Haemophilus influenzae type b vaccine or other relevant disease preventions. It also indicated a need to re-evaluate the health insurance policy for children under 6 years old, so that the unnecessarily high out-of-pocket costs of these diseases are reduced.


Subject(s)
Cost of Illness , Health Care Costs/statistics & numerical data , Hospital Costs/statistics & numerical data , Meningitis/economics , Meningitis/therapy , Pneumonia/economics , Pneumonia/therapy , Child, Preschool , Female , Health Expenditures/statistics & numerical data , Hospitalization/economics , Humans , Infant , Infant, Newborn , Male , Prospective Studies , Tertiary Care Centers/economics , Vietnam
11.
PLoS One ; 8(11): e79880, 2013.
Article in English | MEDLINE | ID: mdl-24278203

ABSTRACT

OBJECTIVE: To estimate the direct and indirect costs of meningitis to households in the Kassena-Nankana District of Ghana. METHODS: A Cost of illness (COI) survey was conducted between 2010 and 2011. The COI was computed from a retrospective review of 80 meningitis cases answers to questions about direct medical costs, direct non-medical costs incurred and productivity losses due to recent meningitis incident. RESULTS: The average direct and indirect costs of treating meningitis in the district was GH¢152.55 (US$101.7) per household. This is equivalent to about two months minimum wage earned by Ghanaians in unskilled paid jobs in 2009. Households lost 29 days of work per meningitis case and thus those in minimum wage paid jobs lost a monthly minimum wage of GH¢76.85 (US$51.23) due to the illness. Patients who were insured spent an average of GH¢38.5 (US$25.67) in direct medical costs whiles the uninsured patients spent as much as GH¢177.9 (US$118.6) per case. Patients with sequelae incurred additional costs of GH¢22.63 (US$15.08) per case. The least poor were more exposed to meningitis than the poorest. CONCLUSION: Meningitis is a debilitating but preventable disease that affects people living in the Sahel and in poorer conditions. The cost of meningitis treatment may further lead to impoverishment for these households. Widespread mass vaccination will save households' an equivalent of GH¢175.18 (US$117) and impairment due to meningitis.


Subject(s)
Cost of Illness , Meningitis/economics , Adolescent , Adult , Female , Ghana/epidemiology , Humans , Male , Meningitis/epidemiology , Meningitis/therapy , Young Adult
12.
J Acquir Immune Defic Syndr ; 63(3): e101-8, 2013 Jul 01.
Article in English | MEDLINE | ID: mdl-23466647

ABSTRACT

BACKGROUND: Checklists can standardize patient care, reduce errors, and improve health outcomes. For meningitis in resource-limited settings, with high patient loads and limited financial resources, central nervous system diagnostic algorithms may be useful to guide diagnosis and treatment. However, the cost effectiveness of such algorithms is unknown. METHODS: We used decision analysis methodology to evaluate the costs, diagnostic yield, and cost effectiveness of diagnostic strategies for adults with suspected meningitis in resource-limited settings with moderate/high HIV prevalence. We considered 3 strategies: (1) comprehensive "shotgun" approach of utilizing all routine tests; (2) "stepwise" strategy with tests performed in a specific order with additional tuberculosis (TB) diagnostics; (3) "minimalist" strategy of sequential ordering of high-yield tests only. Each strategy resulted in 1 of 4 meningitis diagnoses: bacterial (4%), cryptococcal (59%), TB (8%), or other (aseptic) meningitis (29%). In model development, we utilized prevalence data from 2 Ugandan sites and published data on test performance. We validated the strategies with data from Malawi, South Africa, and Zimbabwe. RESULTS: The current comprehensive testing strategy resulted in 93.3% correct meningitis diagnoses costing $32.00 per patient. A stepwise strategy had 93.8% correct diagnoses costing an average of $9.72 per patient, and a minimalist strategy had 91.1% correct diagnoses costing an average of $6.17 per patient. The incremental cost-effectiveness ratio was $133 per additional correct diagnosis for the stepwise over minimalist strategy. CONCLUSIONS: Through strategically choosing the order and type of testing coupled with disease prevalence rates, algorithms can deliver more care more efficiently. The algorithms presented herein are generalizable to East Africa and Southern Africa.


Subject(s)
Checklist , Health Resources/economics , Meningitis/diagnosis , Algorithms , Cost-Benefit Analysis , Developing Countries , HIV Infections/diagnosis , HIV Infections/economics , Humans , Malawi , Meningitis/economics , Meningitis/mortality , Patient Care , South Africa , Survival Rate , Uganda , Zimbabwe
13.
J Health Popul Nutr ; 28(5): 436-42, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20941894

ABSTRACT

The aim of this study was to estimate the costs of treatment of children who present with the signs and symptoms of invasive bacterial diseases in Khanh Hoa province, Viet Nam. The study was an incidence-based cost-of-illness analysis from the health system perspective. The hospital costs included labour, materials and capital costs, both direct and indirect. Costs were determined for 980 children, with an average age of 12.67 months (standard deviation +/- 11.38), who were enrolled in a prospective surveillance at the Khanh Hoa General Hospital during 2005-2006. Of them, 57% were male. By disease-category, 80% were suspected of having pneumonia, 8% meningitis, 3% very severe disease consistent with pneumococcal sepsis, and 9% other diseases. Treatment costs for suspected pneumonia, meningitis, very severe disease, and other diseases were US$ 31, US$ 57, US$ 73, and US$ 24 respectively. Costs ranged from US$ 24 to US$ 164 across different case-categories. Both type of disease and age of patient had statistically significant effects on treatment costs. The results showed that treatment costs for bacterial diseases in children were considerable and might differ by as much as seven times among invasive pneumococcal diseases. Changes in costs were sensitive to both age of patient and case-category. These cost-of-illness data will be an important component in the overall evidence base to guide the development of vaccine policy in Viet Nam.


Subject(s)
Hospital Costs/statistics & numerical data , Meningitis/economics , Pneumonia/economics , Sepsis/economics , Child, Preschool , Female , Hospitalization/economics , Hospitals, General/economics , Hospitals, General/statistics & numerical data , Humans , Infant , Male , Models, Economic , Vietnam
14.
Int J Health Plann Manage ; 21(3): 229-38, 2006.
Article in English | MEDLINE | ID: mdl-17044548

ABSTRACT

Pneumonia, meningitis, and sepsis place a significant economic burden on health care systems, particularly in developing countries. This study estimates treatment costs for these diseases in health facilities in the Northern Areas of Pakistan. Health facility resources are organized by categories--including salaries, capital costs, utilities, overhead, maintenance and supplies--and quantified using activity-based costing (ABC) techniques. The average cost of treatment for an outpatient case of child pneumonia is dollar 13.44. For hospitalized care, the health system spent an average of dollar 71 per episode for pneumonia, dollar 235 for severe pneumonia, and dollar 2,043 for meningitis. These costs provide important background information for the potential introduction of the conjugate Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae vaccines in Pakistan.


Subject(s)
Ambulatory Care/economics , Health Care Costs , Hospitalization/economics , Meningitis/economics , Pneumonia/economics , Child, Preschool , Cost Allocation , Cost of Illness , Humans , Infant , Meningitis/drug therapy , Meningitis/prevention & control , Pakistan , Pneumonia/drug therapy , Pneumonia/prevention & control , Vaccines, Conjugate/economics
19.
Pediatr Infect Dis J ; 21(5): 361-5, 2002 May.
Article in English | MEDLINE | ID: mdl-12150168

ABSTRACT

BACKGROUND: Pneumococcal conjugate vaccine for infants has recently been found to be effective for prevention of meningitis, bacteremia, pneumonia and otitis media, but it is more costly than previously introduced vaccines. AIM: We sought to determine the savings in medical costs through 36 months of life attributable to the use of the vaccine in healthy infants in a large randomized trial. METHODS: We analyzed the actual medical costs of 36 471 children involved in a randomized trial of heptavalent pneumococcal conjugate vaccine conducted in the Northern California Kaiser Permanente Medical Care Program. The costs of the vaccine and vaccine administration were excluded. RESULTS: Compared with the control group, the vaccinated group experienced a 2% reduction in clinic related costs [$48; 95% confidence interval (CI), $10 to $83] and a nearly significant 14% reduction in outpatient hospitalization costs ($32; CI -$1 to $66). The savings in total medical costs were 1.2%, but this difference was not significant ($41; CI -$204 to $270). Inpatient hospital costs were highly variable and were responsible for the lack of precision in the difference in total cost. In a post hoc analysis that excluded hospital costs not believed to be potentially pneumococcal related, savings in medical costs were $78 and significant (CI $5 to $158). CONCLUSIONS: The pneumococcal conjugate vaccine reduced ambulatory care costs in children in the first 36 months of life, but without a larger trial, the magnitude of the savings in total medical costs is uncertain. These results indicate, however, that any medical cost savings that are associated with the vaccine are unlikely to be high enough to offset the cost of the vaccine at its current price.


Subject(s)
Health Care Costs/statistics & numerical data , Pneumococcal Vaccines/economics , Randomized Controlled Trials as Topic , Bacteremia/economics , Bacteremia/prevention & control , Child, Preschool , Cost Savings , Female , Hospitalization , Humans , Infant , Infant, Newborn , Male , Meningitis/economics , Meningitis/prevention & control , Otitis Media/economics , Otitis Media/prevention & control , Pneumococcal Vaccines/therapeutic use , Pneumonia/economics , Pneumonia/prevention & control , Vaccines, Conjugate/economics , Vaccines, Conjugate/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...